Research programme: metabolic disorder therapeutics - Synlogic/Ginkgo Bioworks
Latest Information Update: 28 Apr 2026
At a glance
- Originator Ginkgo Bioworks; Synlogic
- Developer Synlogic
- Class Antigouts; Bacteria
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gout; Hyperuricaemia; Metabolic disorders
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for preclinical development in Gout in USA (PO)
- 28 Apr 2026 No recent reports of development identified for preclinical development in Hyperuricaemia in USA (PO)
- 28 Oct 2025 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (PO)